Ortataxel
From Self-sufficiency
| File:Ortataxel.png | |
| Systematic (IUPAC) name | |
|---|---|
|
(3aS,4R,7R,8aS,9S,10aR,12aS,13S,13aS)-7,12a-bis(acetyloxy)-4-({(2R,3S)-3-[tert-butoxycarbonyl)amino]-2-hydroxy-5-methylhexanoyl}oxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano[1,3]dioxolo[8,9]cyclodeca[1,2-d][1]benzoxet-13-yl benzoate | |
| Identifiers | |
| CAS Number | 186348-23-2 |
| ATC code | none |
| PubChem | CID 10557575 |
| Chemical data | |
| Formula | C44H57NO17 |
| Molar mass | 871.92 g/mol[[Script error: No such module "String".]] |
Ortataxel is a drug used in chemotherapy. As of June 2009[update], Spectrum Pharmaceuticals has the drug is in a Phase 2 clinical trial.
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from June 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Antineoplastic drugs
- Benzoates
- Carbamates
- Alcohols
- Ketones
- Acetate esters
- Antineoplastic and immunomodulating drug stubs
